Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Blood (2024) 144 (Supplement 1): 4685.1.

https://doi.org/10.1182/blood-2024-208457

Published: 2024

Journal Articles

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 1): 308.

https://doi.org/10.1182/blood-2024-209438

Published: 2024

Journal Articles

Results of an Open-Label Phase 1 Study Repurposing Oral Metformin and Nelfinavir in Combination with Subcutaneous Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Ibrahim Alodhaibi, Sikander Ailawadhi, Gaby E Perez Burbano, Patrick O'Brien, Francis Buadi, Suzanne R. Hayman, Shaji Kunnathu Kumar, Wilson I. Gonsalves

Blood (2023) 142 (Supplement 1): 6733.

https://doi.org/10.1182/blood-2023-182958

Published: 2023

Journal Articles

Chronic Lymphocytic Leukemia, T-Cell Large Granular Lymphocytic Leukemia in a Pediatric Patient without Underlying Condition

Urvi Kapoor, Yara E Perez, Yaoping Zhang

Blood (2021) 138 (Supplement 1): 4701.

https://doi.org/10.1182/blood-2021-154064

Published: 2021

Journal Articles

a Combination of Ex Vivo and Computational Models Predicts Clinical Response in MM Treatment Combinations of Proteasome Inhibitors, Imids, Nuclear Export Inhibitors and Alkylating Agents

Ariosto Silva, PhD, Maria Silva, M.Sc, Timothy Jacobson, B.S., Mark B Meads, PhD, Allison Distler, B.S., Aunshka Collins, BS, Chris Cubitt, PhD, Lia E Perez, MD, Rachid Baz, MD, Dmitri Rebatchouk, PhD, Robert Gatenby, MD, PhD, Kenneth H. Shain, MD PhD

Blood (2016) 128 (22): 3291.

https://doi.org/10.1182/blood.V128.22.3291.3291

Published: 2016

Journal Articles

Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry

Blood (2015) 126 (23): 4231.

https://doi.org/10.1182/blood.V126.23.4231.4231

Published: 2015

Journal Articles

Bam Regimen Followed By High-Dose Therapy and Autologous Stem Cell Transplantation As First-Line Treatment Of Primary Central Nervous System Lymphoma: A Multicenter Study From Spanish Group GEL-TAMO

Blood (2013) 122 (21): 4349.

https://doi.org/10.1182/blood.V122.21.4349.4349

Published: 2013

Journal Articles

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Mohamed A Kharfan-Dabaja, MD, Claudio Anasetti, MD, Nathalie Luis, B.S., Linda Brand, R.N., Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Jose Leonel Ochoa-Bayona, M.D., Taiga Nishihori, MD, Lia E Perez, MD, Ernesto Ayala, MD, Javier Pinilla-Ibarz, MD, PhD, Lubomir Sokol, MD, PhD, Joseph Pidala, MD, MS, Frederick L Locke, MD, Eduardo M. Sotomayor, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 3022.

https://doi.org/10.1182/blood.V118.21.3022.3022

Published: 2011

Journal Articles

Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis.

Lia E. Perez, MD, Nancy Parquet, BS, Marina Molisano, BS, Ken Shain, Ph.D, Melisa Alsina, MD, Claudio Anasetti, MD, William Dalton, Ph.D. MD

Blood (2007) 110 (11): 3521.

https://doi.org/10.1182/blood.V110.11.3521.3521

Published: 2007

Journal Articles

Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.

M. Alcoceba, L. Marin, A. Balanzategui, M.E. Sarasquete, PhD, P. Martin-Jimenez, PhD, M.C. Chillon, PhD, M. Vargas, R. Corral, MD, E. Perez, MD, J. Fernandez-Calvo, MD, PhD, A. Martinez, MD, PhD, J.M. Hernandez, MD, PhD, Joan Blade, MD, PhD, J.J. Lahuerta, MD, PhD, R. Garcia-Sanz, MD, PhD, M. Gonzalez, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 1481.

https://doi.org/10.1182/blood.V110.11.1481.1481

Published: 2007

Journal Articles

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Lia E. Perez, MD, Nancy Parquet, BS, Ramadevi Nimmanapalli, DVM, PhD, Melissa Alsina, M.D, Claudio Anasetti, MD, William Dalton, PhD MD

Blood (2005) 106 (11): 2489.

https://doi.org/10.1182/blood.V106.11.2489.2489

Published: 2005

Journal Articles

Combination Chemotherapy with Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Induces a High Response Rate in Previously Untreated CLL.

Francesc Bosch, A. Ferrer, N. Villamor, E. Gine, M.A. Abella, S. Gardella, J. Besalduch, M. Gonzalez, A. Altes, L. Escoda, S. Ferrer, E. Gonzalez-Barca, E. Perez-Ceballos, A. Asensi, E. Montserrat

Blood (2005) 106 (11): 718.

https://doi.org/10.1182/blood.V106.11.718.718

Published: 2005

Journal Articles

SH2-Containing-5′Inositol Phosphatase-1 (SHIP) Regulates Megakaryocytic Progenitors Numbers (MKP) and Determines Megakaryocyte (MK) In Vivo Localization.

Lia E. Perez, M.D., Caroline Desponts, B.S., Nancy Parquet, B.S., William G. Kerr, Ph.D.

Blood (2004) 104 (11): 2780.

https://doi.org/10.1182/blood.V104.11.2780.2780

Published: 2004

Journal Articles

Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR).

Nancy Parquet, B.S., Ramadevi Nimmanapalli, D.V.M. Ph.D., Claudio Anasetti, M.D., Melissa Alsina, M.D., William Dalton, Ph.D. M.D., Lia E. Perez, M.D.

Blood (2004) 104 (11): 2459.

https://doi.org/10.1182/blood.V104.11.2459.2459

Published: 2004

Journal Articles

Xenotransplantation of immunodeficient mice with mobilized human blood CD34 + cells provides an in vivo model for human megakaryocytopoiesis and platelet production

Lia E. Perez, Henry M. Rinder, Chao Wang, Jayne B. Tracey, Noel Maun, Diane S. Krause

Blood (2001) 97 (6): 1635–1643.

https://doi.org/10.1182/blood.V97.6.1635

Published: 2001

Journal Articles

The Effect of "Minute" and "Titrated" Amounts of Folic Acid on the Megaloblastic Anemia of Tropical Sprue

T. W. SHEEHY, M.C., M. E. RUBINI, M.D., E. PEREZ-SANTIAGO, M.D., R. SANTINI, JR., Ph.D., J. HADDOCK, M.D.

Blood (1961) 18 (6): 623–636.

https://doi.org/10.1182/blood.V18.6.623.623

Published: 1961

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Results of an Open-Label Phase 1 Study Repurposing Oral Metformin and Nelfinavir in Combination with Subcutaneous Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma

Chronic Lymphocytic Leukemia, T-Cell Large Granular Lymphocytic Leukemia in a Pediatric Patient without Underlying Condition

a Combination of Ex Vivo and Computational Models Predicts Clinical Response in MM Treatment Combinations of Proteasome Inhibitors, Imids, Nuclear Export Inhibitors and Alkylating Agents

Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry

Bam Regimen Followed By High-Dose Therapy and Autologous Stem Cell Transplantation As First-Line Treatment Of Primary Central Nervous System Lymphoma: A Multicenter Study From Spanish Group GEL-TAMO

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis.

Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.

Microenvironment Confers Resistance to TRAIL Mediated Apoptosis.

Combination Chemotherapy with Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Induces a High Response Rate in Previously Untreated CLL.

SH2-Containing-5′Inositol Phosphatase-1 (SHIP) Regulates Megakaryocytic Progenitors Numbers (MKP) and Determines Megakaryocyte (MK) In Vivo Localization.

Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR).

Xenotransplantation of immunodeficient mice with mobilized human blood CD34 + cells provides an in vivo model for human megakaryocytopoiesis and platelet production

The Effect of "Minute" and "Titrated" Amounts of Folic Acid on the Megaloblastic Anemia of Tropical Sprue

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only